drugset / Trial / NCT05882487
Safety and Efficacy Study of KL002 in the Treatment of Advanced Primary PD
Phase 0
Unknown
9 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
R&D Kanglin Biotech · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a non-randomized, open label, dose-escalation study to evaluate the safety and efficacy of KL002 in the treatment of advanced primary Parkinson's disease. Condition or disease: Parkinson's Disease Intervention/treatment: Drug: KL002 Phase: NA
Timeline
- Start
- 2023-06-01
- Primary completion
- 2026-04-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KL002 | Unknown | — | Other |